Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648768 | 0.89 | CA1 (0.52) | SLC6A2SLC6A3SLC6A4CASP3CA1 | |
| SCHEMBL13712221 | 0.81 | MAPT (0.45) | SLC6A3CASP3CA1CA2MEN1 | |
| SCHEMBL7978849 | 0.75 | LMNA (0.48) | FFAR1FFAR4HCAR2 | |
| SCHEMBL16810267 | 0.74 | SLC6A3 (0.94) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL13488448 | 0.74 | KMT2A (0.38) | SLC6A2SLC6A3SLC6A4FFAR1MEN1 | |
| SCHEMBL10733709 | 0.73 | PPARG (0.51) | FFAR1CA1CA2FFAR4HCAR2 | |
| SCHEMBL13488443 | 0.72 | FFAR1 (0.42) | FFAR1CA1CA2MEN1KMT2A | |
| SCHEMBL12986781 | 0.71 | CASP3 (0.54) | CASP3CA1CA2 | |
| SCHEMBL17158407 | 0.71 | CA1 (0.80) | FFAR1CA1CA2MEN1KMT2A | |
| SCHEMBL20183802 | 0.71 | CA1 (0.80) | FFAR1CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445481-B2 | Scaffold-diversified pyrrolidinone derivatives and their use | THE UNIVERSITY OF CHICAGO (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445481-B2 | Scaffold-diversified pyrrolidinone derivatives and their use | THE UNIVERSITY OF CHICAGO (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100035892-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | THE UNIVERSITY OF CHICAGO | 2010-02-11 | — | — | US | disclosed |
| US-20100035892-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | THE UNIVERSITY OF CHICAGO | 2010-02-11 | — | — | US | disclosed |
| WO-2008103382-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | KOZMIN SERGEY (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035892-A1 | METHOD FOR ASSEMBLING HIGH-PURITY CHEMICAL LIBRARIES, COMPOUNDS SUPPRESSING ACETYL COENZYME A CARBOXYLASE ACTIVITIES DISCOVERED BY SAME | ACACA, COASY, ACACB | SLC6A2 4858/4885SLC6A3 4833/4885SLC6A4 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.